Skip to content

D&A at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
$2B+13.1%
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
$123.2M-2.9%
Boston Scientific logo
Boston ScientificBSX
$351M+8.0%
The Cooper Companies, Inc. logo
The Cooper Companies, Inc.COO
$95.4M+3.0%
Exelixis logo
ExelixisEXEL
$6.95M-5.4%

Segments

By geography

See full
US$8.22M

Other financials

Income statement

See full
Revenue$150.6M+41.2%
Gross profit$117.2M+42.4%
Operating income-$19.9M+4.0%
Net income-$19.8M-9.0%
EPS (diluted)-$0.34-6.3%

Balance sheet

See full
Cash & equivalents$104.2M-8.8%
Total debt$105.9M-1.7%
Total equity$670.9M-12.2%
Total assets$893.3M-7.5%

Cash flow

See full
Operating cash flow-$12.5M+32.4%
CapEx$4.0M+104%
Free cash flow-$16.5M+19.4%

Valuation

See full
Market cap$7.68B+12.3%
Enterprise value$7.68B+12.5%
P/S13.9×-3.0×

Profitability

See full
Gross margin78.1%+2.3pp
Operating margin-36.1%+24.3pp
Net margin-34.3%+4.8pp
FCF margin-13.2%-3.9pp

Returns & leverage

See full
Return on equity-26.4%+11.1pp
Debt / equity0.2×0.0×
Current ratio5.4×-1.1×

Where this comes from

Reported directly by Glaukos in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Glaukos’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Glaukos's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Glaukos's D&A?
Glaukos (GKOS) reported D&A of $2.91M in Q1 2026.
How has Glaukos's D&A changed year-over-year?
Glaukos's D&A increased by 9.7% year-over-year, from $2.65M to $2.91M.
What is the long-term trend for Glaukos's D&A?
Over 4 years (2021 to 2025), Glaukos's D&A has grown at a -22.0% compound annual growth rate (CAGR), from $29.66M to $10.97M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.